Shukra Pharmaceuticals (524632) Q2 26/27 earnings summary

Executive summary

• Board approved unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026; consolidated Q2 net profit was 1,271.19 lakh and H1 net profit was 2,567.04 lakh.

• Consolidated results include eight subsidiaries; their reported aggregate net losses were 329.99 lakh for Q2 and 537.13 lakh for H1, before consolidation adjustments.

Financial highlights

• Consolidated Q2 revenue from operations was 4,420.38 lakh, versus 587.74 lakh in Q2 FY25; H1 revenue was 6,772.61 lakh, versus 1,126.85 lakh in H1 FY25.

• Consolidated Q2 PBT was 1,782.84 lakh and net profit 1,271.19 lakh, versus 19.84 lakh and 237.81 lakh, respectively, in Q2 FY25.

• Consolidated H1 PBT was 3,600.02 lakh and net profit 2,567.04 lakh, versus 157.16 lakh and 340.77 lakh in H1 FY25; H1 basic and diluted EPS were ₹0.58.

• Standalone Q2 revenue from operations was 4,420.38 lakh, PBT 2,112.85 lakh and net profit 1,601.20 lakh; H1 net profit was 3,104.18 lakh and EPS ₹0.71.

Segment performance

• Consolidated Q2 segment revenue was 3,226.93 lakh for Shukra Pharmaceutical and 1,250.65 lakh for Shukra MedTech; segment results before tax and interest were 1,506.40 lakh and 309.66 lakh, respectively.

• Consolidated H1 segment revenue was 5,633.13 lakh for Shukra Pharmaceutical and 1,250.65 lakh for Shukra MedTech; respective segment results before tax and interest were 3,366.53 lakh and 309.66 lakh.

• Shukra MedTech segment naming became effective October 1, 2025, so the current segment period has no corresponding MedTech segment in the prior-year comparative.